

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.co

Zydus launches Semaglutide Injection in reusable multi-dose pen device in India

21 March 2026 | News

Drug will be launched under the brand names - SEMAGLYN, MASHEMA and ALTERME



Ahmedabad-based Zydus Lifesciences has launched Semaglutide Injection under the brand names – SEMAGLYN, MASHEMA and ALTERME, upon patent expiry in India. The Drug Controller General of India (DCGI) had earlier provided its approval for manufacturing and marketing Semaglutide injection for the treatment of both Type 2 Diabetes Mellitus and Obesity indications.

Unlike current treatment options, which often require patients to purchase multiple single-dose pens as they progressively titrate their dosage, Zydus offers an innovative reusable multi-dose novel pen device. This advancement will enable clinicians and patients to conveniently select and administer different dose strengths from a single pen, thereby improving adherence, enhancing convenience, and significantly lowering the overall therapy cost.

Zydus' Semaglutide injection will be available in 15mg/3ml cartridge and will be manufactured at Zydus Biotech Park, Ahmedabad. The average monthly cost of the treatment will be approximately Rs. 2,200.

Diabetes and obesity are among India's most serious health challenges today. Treatments based on GLP-1 have the potential to play an important role in addressing this growing public health concern. According to the International Diabetes Federation, 8.9 crore adults in India are living with diabetes, which is 10.5 per cent of the country's adult population. At the same time, obesity is rising rapidly across age groups.